A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

Sponsor ID
VIS171-101
Clinicaltrials.gov ID
NCT05418101
EudraCT ID
2021-006246-12
EUCTIS ID
N/A
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information
N/A
Study Complete
Sponsor ID
VIS171-101
Trial Details
Subscribe for updates
Age
18 - 75 Years
Therapeutic Area
  • Autoimmune Disease
    • Sex
    Female & Male
    Trial Dates
    Apr 2022 - Mar 2024
    Healthy Volunteers
    Yes
    • Inclusion criteria for both Part A and Part B:
    • Male or female participant between 18 and 55 years of age, inclusive, at the screening visit (Part A and Part B \[participants with selected autoimmune diseases\]) or between 18 and 75 years of age, inclusive, at the screening visit (Part B \[participants with specific autoimmune disease\]).
    • Body mass index between 17 and 35 kg/m\^2.
    • Female participants will be nonpregnant, nonlactating, and either postmenopausal for at least 2 years or surgically sterile for at least 3 months.
    • Male participants with female partners of childbearing potential must agree to use double barrier contraception or abstain from sex during the study and until 90 days following the last dose of study intervention.
    • Additional inclusion criterion for Part A:
    • \- Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations).
    • Additional inclusion criteria for Part B (participants with specific autoimmune disease\[s\]):
    • Diagnosis of a specified autoimmune disease based on standard criteria for the condition.
    • Other criteria may apply depending on the autoimmune condition.
    • Exclusion criteria for both Part A and Part B:
    • Prior and Concomitant Therapy
    • Receipt of high dose corticosteroid therapy within 4 weeks prior to screening.
    • Receipt of belimumab within 6 months prior to screening.
    • History of treatment with rituximab or ocrelizumab (or other B cell-depleting agent) within 12 months prior to screening.
    • History of cytotoxic medications within the preceding 12 months.
    • Receipt of blood products within 6 months prior to screening.
    • Prior/Concurrent Clinical Study Experience:
    • Receipt of any investigational product within 4 weeks or 5 half-lives of the respective product prior to signing of the ICF, whichever is greater.
    • Currently participating in another clinical study of any investigational drug, device, or intervention.
    • Diagnostic Assessments
    • Participants with uncontrolled hypertension (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg in any position) or symptomatic hypotension.
    • Any chronic infectious disease.
    • Participant with a positive urine drug or alcohol breath screen test result at screening.
    • Other Exclusions:
    • Any participant who has a history of alcohol or drug/chemical abuse.
    • Participant who has donated \> 500 mL of blood within 60 days prior to the start of screening or any plasma within 7 days prior to baseline (Day -1).
    • History of opportunistic infection requiring hospitalization or intravenous (IV) antimicrobial treatment within 1 year prior to randomization.
    • History of major surgery within 12 weeks of screening or will require major surgery during the study.
    • Clinically significant electrocardiographic abnormalities, at screening.
    • A QT interval corrected for heart rate using Fridericia's correction (QTcF) \> 450 msec for male participants or \> 470 msec for female participants at screening.
    • Participant has received an organ transplant.
    • History of any significant cardiovascular disease or thrombotic episode.
    • History of cancer, apart from: squamous or basal cell carcinoma of the skin that has been successfully treated; cervical cancer in situ that has been successfully treated.
    • Coronavirus Disease 2019 (COVID-19): current symptoms of infection; diagnosis of COVID-19 in the 21 days prior to Screening; ongoing diagnosis of "Long-COVID" symptoms.
    • Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose.
    • Additional exclusion criteria for Part A:
    • Medical Conditions
    • Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or malignancy.
    • Participant has a history or presence of proteinuria, chronic kidney disease, disease requiring immunosuppressive therapy (including systemic steroids), or is considered to be immunosuppressed for any other reason.
    • History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
    • Known immunodeficiency disorder.
    • History of chronic infection or any infection requiring hospitalization or treatment with antivirals, antibiotics, or antifungal therapy within 30 days prior to administration of the study intervention.
    • Alanine transaminase (ALT) or aspartate transaminase (AST) \> 1.5 × the upper limit of normal (ULN).
    • Total bilirubin \> 1.5 × ULN (isolated bilirubin \> 1.5 × ULN is acceptable if total bilirubin is fractionated and direct bilirubin \< 35%).
    • Known hepatic or biliary abnormalities.
    • Additional exclusion criterion for Part A and Part B (participants with participants with specific autoimmune disease may apply depending upon the autoimmune condition).

    Study Summary

    This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).

    Additional Study Details

    Phase
    Phase 1
    Study Drug
    Drug: VIS171
    Type
    Interventional
    Masking
    None (Open Label)
    Estimated Enrollment
    61
    Additional Study Details

    Inclusion and Exclusion Criteria

    Inclusion Criteria

    • Inclusion criteria for both Part A and Part B:
    • * Male or female participant between 18 and 55 years of age, inclusive, at the screening visit (Part A and Part B \[participants with selected autoimmune diseases\]) or between 18 and 75 years of age, inclusive, at the screening visit (Part B \[participants with specific autoimmune disease\]).

    Exclusion Criteria

    • Exclusion criteria for both Part A and Part B:
    • Prior and Concomitant Therapy
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    • Inclusion criteria for both Part A and Part B:
    • Male or female participant between 18 and 55 years of age, inclusive, at the screening visit (Part A and Part B \[participants with selected autoimmune diseases\]) or between 18 and 75 years of age, inclusive, at the screening visit (Part B \[participants with specific autoimmune disease\]).
    • Body mass index between 17 and 35 kg/m\^2.
    • Female participants will be nonpregnant, nonlactating, and either postmenopausal for at least 2 years or surgically sterile for at least 3 months.
    • Male participants with female partners of childbearing potential must agree to use double barrier contraception or abstain from sex during the study and until 90 days following the last dose of study intervention.
    • Additional inclusion criterion for Part A:
    • \- Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations).
    • Additional inclusion criteria for Part B (participants with specific autoimmune disease\[s\]):
    • Diagnosis of a specified autoimmune disease based on standard criteria for the condition.
    • Other criteria may apply depending on the autoimmune condition.
    Exclusion Criteria:
    • Exclusion criteria for both Part A and Part B:
    • Prior and Concomitant Therapy
    • Receipt of high dose corticosteroid therapy within 4 weeks prior to screening.
    • Receipt of belimumab within 6 months prior to screening.
    • History of treatment with rituximab or ocrelizumab (or other B cell-depleting agent) within 12 months prior to screening.
    • History of cytotoxic medications within the preceding 12 months.
    • Receipt of blood products within 6 months prior to screening.
    • Prior/Concurrent Clinical Study Experience:
    • Receipt of any investigational product within 4 weeks or 5 half-lives of the respective product prior to signing of the ICF, whichever is greater.
    • Currently participating in another clinical study of any investigational drug, device, or intervention.
    • Diagnostic Assessments
    • Participants with uncontrolled hypertension (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg in any position) or symptomatic hypotension.
    • Any chronic infectious disease.
    • Participant with a positive urine drug or alcohol breath screen test result at screening.
    • Other Exclusions:
    • Any participant who has a history of alcohol or drug/chemical abuse.
    • Participant who has donated \> 500 mL of blood within 60 days prior to the start of screening or any plasma within 7 days prior to baseline (Day -1).
    • History of opportunistic infection requiring hospitalization or intravenous (IV) antimicrobial treatment within 1 year prior to randomization.
    • History of major surgery within 12 weeks of screening or will require major surgery during the study.
    • Clinically significant electrocardiographic abnormalities, at screening.
    • A QT interval corrected for heart rate using Fridericia's correction (QTcF) \> 450 msec for male participants or \> 470 msec for female participants at screening.
    • Participant has received an organ transplant.
    • History of any significant cardiovascular disease or thrombotic episode.
    • History of cancer, apart from: squamous or basal cell carcinoma of the skin that has been successfully treated; cervical cancer in situ that has been successfully treated.
    • Coronavirus Disease 2019 (COVID-19): current symptoms of infection; diagnosis of COVID-19 in the 21 days prior to Screening; ongoing diagnosis of "Long-COVID" symptoms.
    • Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose.
    • Additional exclusion criteria for Part A:
    • Medical Conditions
    • Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or malignancy.
    • Participant has a history or presence of proteinuria, chronic kidney disease, disease requiring immunosuppressive therapy (including systemic steroids), or is considered to be immunosuppressed for any other reason.
    • History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
    • Known immunodeficiency disorder.
    • History of chronic infection or any infection requiring hospitalization or treatment with antivirals, antibiotics, or antifungal therapy within 30 days prior to administration of the study intervention.
    • Alanine transaminase (ALT) or aspartate transaminase (AST) \> 1.5 × the upper limit of normal (ULN).
    • Total bilirubin \> 1.5 × ULN (isolated bilirubin \> 1.5 × ULN is acceptable if total bilirubin is fractionated and direct bilirubin \< 35%).
    • Known hepatic or biliary abnormalities.
    • Additional exclusion criterion for Part A and Part B (participants with participants with specific autoimmune disease may apply depending upon the autoimmune condition).

    Locations

    Location
    Status
    Location
    UMHAT
    Plovdiv, Bulgaria, 4002
    Status
    N/A
    Location
    Ambulatory for Specialized Medical Help - skin and venereal diseases
    Sofia, Bulgaria, 1407
    Status
    N/A
    Location
    Comac Medical Ltd
    Sofia, Bulgaria, 1612
    Status
    N/A
    Location
    MBAL Sveta Sofia
    Sofia, Bulgaria, 1618
    Status
    N/A
    Location
    Diagnostic and Consultative Center Convex EOOD
    Sofia, Bulgaria, 1680
    Status
    N/A
    Location
    Universitaetsklinikum Bonn AöR
    Bonn, Germany, 53127
    Status
    N/A
    Showing {first} - {last} of {total} Results

    © 2026 Otsuka America Pharmaceutical, Inc.

    All rights reserved.

    January 2026 01US25EUC0489

    We defy limitation,

    so that others can too.

    Follow Us
    OAPI and OPDC Locations

    508 Carnegie Center Dr,

    Princeton, NJ 08540, United States

    Phone +1 609-524-6788

    2440 Research Blvd,

    Rockville, MD 20850, United States

    Phone +1 301-424-9055

    3956 Point Eden Way

    Hayward, CA 94545, United States

    Phone +1 800-562-3974